November 13, 2019

PPMD Certifies Motol University Hospital in the Czech Republic

PPMD is thrilled that Motol University Hospital will be the second Global Certified Duchenne Care Center.  Together with the Parent Project Czech Republic advocacy group, Jana Haberlova and the team at Motol University Hospital are doing an…

Learn More

November 12, 2019

The Duchenne Registry App is Available Now!

After twelve years of collecting data to advance research for Duchenne, PPMD’s Duchenne Registry is excited to share the new and improved Duchenne Registry Mobile App with our community of patients and caregivers! We believe the app will make…

Learn More

November 12, 2019

Solid Biosciences Provides SGT-001 Program Update

Solid Biosciences Inc. provided a clinical update on SGT-001 and reported that the FDA has notified the company that IGNITE DMD, its Phase I/II study of SGT-001, has been placed on clinical hold. To date,…

Learn More

November 8, 2019

Join the 2020 PPMD Adult Advisory Committee! Application Deadline: Friday, November 15

Been looking for a way to engage with the community a bit more? Have personal experience that you’d like to see be better reflected in national policy and program efforts? Interested in serving as a…

Learn More

November 6, 2019

Roche/Genentech Announces Decision to Discontinue Development of RG6206 (RO7239361)

We are disappointed to learn that Roche/Genentech is discontinuing development of their investigational anti-myostatin adnectin RG6206 (RO7239361) for the treatment of Duchenne. According to the company, this decision was based on results from a pre-planned…

Learn More

November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people,  including families, an amazing group of volunteers in our kids room, six members of…

Learn More

October 30, 2019

PPMD Launches Interactive Drug Development Pipeline

For over twenty five years, Parent Project Muscular Dystrophy has been committed to exploring and supporting innovative therapeutic possibilities. We take a cutting-edge approach to accelerate finding treatments that will end Duchenne for every single…

Learn More

October 24, 2019

PPMD Awards $148,000 in Grants to Improve Cardiac Function in Duchenne

Parent Project Muscular Dystrophy (PPMD) is excited to announce that Dr. Kan Hor from Nationwide Children’s Hospital and Dr. Dongsheng Duan from the University of Missouri received grants to further develop their research into potential…

Learn More

October 22, 2019

Reveragen Biopharma Receives NIH Ethics Grant to Return Data to Participants in Vamorolone Clinical Trials

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded an ethics research grant to ReveraGen BioPharma to return patient-level and aggregate data to Duchenne patients and…

Learn More

October 22, 2019

WATCH: DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen – Webinar Recording

Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage…

Learn More